Baidu
map

Liver Int:基因鉴定用于预测严重肝脏疾病的价值有限

2018-03-10 MedSci MedSci原创

基因型鉴定用于预测存在危险因素的严重肝脏疾病,价值有限

研究背景:慢性肝病是一项重大的全球公共卫生挑战。无症状的、高危患者在初级护理中使用非侵入性的方法,有潜能通过识别有疾病进展的患者,来解决这一问题。因此,本研究评估了与非酒精性脂肪肝(NAFLD)相关的基因位点,是否可以作为有疾病危险因素的肝损伤患者的基因决定因素。

研究方法:本研究为观察性的横断面研究。在患有2型糖尿病和或BMI>27.3的467例患者中检测了纤维化和脂肪肝标志物-三型前胶原(PIIINP)水平。通过是否存在PNPLA3 (rs738409), GCKR (rs1260326)和TM6SF2 (rs58542926)等的特异性危险等位基因,对患者进行基因鉴定;并评估与血清PIIINP的相关性。

研究结果:PNPLA3, GCKR或TM6SF2中危险等位基因的出现与疾病危险因素的存在没有相关性;血清PIIINP水平的升高与PNPLA3, GCKR或TM6SF2中危险等位基因的出现同样没有相关性。临床肝病严重的患者(血清PIIINP>11 ng/ml)中出现PNPLA3和GCKR联合变异等位基因的比例更高(P=0.014)。

研究结论:基因型鉴定用于预测存在危险因素的严重肝脏疾病,价值有限。

原始出处

Grove JI, Thiagarajan P, Astbury S, et al. Analysis of genotyping for predicting liver injury marker, Procollagen III in persons at risk of non-alcoholic fatty liver disease. Liver Int, 2018, Mar 1. doi: 10.1111/liv.13733.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1253385, encodeId=9139125338556, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Mar 12 04:27:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294885, encodeId=22e92948858a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Mar 10 15:05:40 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294881, encodeId=9225294881f1, content=学习,了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Mar 10 14:59:08 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1253385, encodeId=9139125338556, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Mar 12 04:27:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294885, encodeId=22e92948858a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Mar 10 15:05:40 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294881, encodeId=9225294881f1, content=学习,了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Mar 10 14:59:08 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-03-10 神功盖世

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1253385, encodeId=9139125338556, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Mar 12 04:27:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294885, encodeId=22e92948858a, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Mar 10 15:05:40 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294881, encodeId=9225294881f1, content=学习,了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Mar 10 14:59:08 CST 2018, time=2018-03-10, status=1, ipAttribution=)]
    2018-03-10 1e0f8808m18(暂无匿称)

    学习,了.谢谢分享.

    0

Baidu
map
Baidu
map
Baidu
map